Bluebird Bio-LentiGlobin gene therapy "carcinogenic" follow-up: clinical research is about to resume

After actively cooperating with the U.

Sickle cell disease (SCD) is a genetic disorder of red blood cells.

On February 16, because sickle cell anemia (SCD) patients who participated in the phase 1 clinical trial of its gene therapy LentiGlobin had acute myeloid leukemia (AML) and myelodysplastic disease (MDS), Bluebird Bio announced , Decided to stop the phase 1/2 (HGB-206) and phase 3 (HGB-210) clinical studies of the drug.

At the same time, because Zynteglo and LentiGlobin used the same lentiviral vector in clinical trials, Bluebird decided to suspend sales of its self-developed, sky-high gene therapy drug Zynteglo for the treatment of thalassemia.

As we all know, Thalassemia is a group of hereditary hemolytic anemia diseases, with approximately 300,000 patients worldwide.

Zynteglo is a gene therapy for the treatment of non-β0β0 genotype transfusion-dependent β-thalassemia patients over 12 years old.

It is reported that Zynteglo was approved for listing in the European Union in June 2019, with a price of 1.

On February 23, 2021, the U.

This caused Bluebird's stock price to plummet by nearly 38%, and the transaction price was about one-third of what it was a year ago.

However, things are hard to come by.